Emmet B. Keeffe Symposium - Insulin Resistance and NAFLD
Algolia Search

Emmet B. Keeffe Symposium - Insulin Resistance and NAFLD

The Division of Gastroenterology & Hepatology, Department of Medicine - Stanford University School of Medicine    

Presents: Emmet B. Keeffe Liver Symposium                               

“Insulin Resistance and Non-Alcoholic Fatty Liver Disease”

Friday, March 9, 2018, 10:00 am - 4:30 pm

Li Ka Shing Center (LKSC), Berg Hall, 2nd Floor

291 Campus Drive, Stanford University

Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the US.  Its prevalence is rising, rapidly becoming a leading cause for liver transplantation.  NAFLD is a part of the systemic manifestations of insulin resistance often seen in patients with prediabetes and diabetes.

This year’s Emmet Keeffe Liver Symposium focuses on NAFLD and insulin resistance.  We will first discuss the latest research on insulin resistance, prediabetes and type II diabetes which is fundamental to the understanding of NAFLD.  The latter part of the symposium will address the clinical aspects of NAFLD in a multidisciplinary fashion.

Our Keynote Speaker this year is Dr. Ira Jacobson, a renowned hepatologist and clinical researcher, who is currently the Director of Hepatology at NYU Langone Medical Center. He will present “NAFLD: state of the art in practice 2018.”